Literature DB >> 18752048

Basal phenotype in breast carcinoma occurring in women aged 35 or younger.

Rita Bori1, Gábor Cserni.   

Abstract

Breast cancer in the young is considered a special clinical presentation of the disease. Sixty-nine breast cancer cases diagnosed at or before the age of 35 were analyzed for common morphological and immunophenotypical features of basal-like carcinomas. Sixteen carcinomas displayed the immunophenotypical characteristics (estrogen receptor and HER2 negativity and positivity for at least one of the following basal markers: cytokeratin 5 or 14, epidermal growth factor receptor, p63) of basal-like carcinomas, and most of them demonstrated characteristic histological features (pushing borders, lymphocytic peritumoral infiltrate, central hypocellular zone or necrosis, high mitotic rate) too. These tumors were more likely to be high-molecular-weight cytokeratin: 34betaE12 and p53 positive by immunohistochemistry. The presence of a basal-like phenotype can be important as concerns systemic treatment issues and could theoretically be associated with a higher rate of BRCA1 mutations in the young, because of the overlap of BRCA1 mutation associated breast carcinomas and the basal-like phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752048     DOI: 10.1007/s12253-008-9090-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

1.  Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus.

Authors:  M Loizidou; Y Marcou; V Anastasiadou; R Newbold; A Hadjisavvas; K Kyriacou
Journal:  Clin Genet       Date:  2007-02       Impact factor: 4.438

2.  Low and high molecular weight cytokeratins in invasive breast carcinoma.

Authors:  H Takei; Y Iino; J Horiguchi; M Maemura; T Oyama; T Yokoe; Y Morishita
Journal:  Oncol Rep       Date:  1997 Jan-Feb       Impact factor: 3.906

3.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.

Authors:  Mehra Golshan; Alex Miron; Asa J Nixon; Judy E Garber; Ethan P Cash; James Dirk Iglehart; Jay R Harris; Julia S Wong
Journal:  Am J Surg       Date:  2006-07       Impact factor: 2.565

5.  Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.

Authors:  R Lidereau; F Eisinger; M H Champème; C Noguès; I Bièche; D Birnbaum; C Pallud; J Jacquemier; H Sobol
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Cytokeratin immunoreactivity in lobular intraepithelial neoplasia.

Authors:  Gary L Bratthauer; Markku Miettinen; Fattaneh A Tavassoli
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Authors:  William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

9.  MRI in the early detection of breast cancer in women with high genetic risk.

Authors:  Giovanna Trecate; Daniele Vergnaghi; Siranuosh Manoukian; Silvana Bergonzi; Gianfranco Scaperrotta; Monica Marchesini; Claudio Ferranti; Bernard Peissel; Gianbattista Spatti; Silvia Bohm; Alberto Conti; Claudia Costa; Manila Sporeni; Franca Podo; Renato Musumeci
Journal:  Tumori       Date:  2006 Nov-Dec

10.  Basal-like breast carcinomas: clinical outcome and response to chemotherapy.

Authors:  S Banerjee; J S Reis-Filho; S Ashley; D Steele; A Ashworth; S R Lakhani; I E Smith
Journal:  J Clin Pathol       Date:  2006-03-23       Impact factor: 3.411

View more
  2 in total

Review 1.  Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Konstantinos Nikolettos; Dimitrios Dimitroulis; Evangelos Diamantis; Paraskevi Farmaki; Alexandros Patsouras; Errika Voutyritsa; Athanasios Syllaios; Constantinos G Zografos; Efstathios A Antoniou; Nikos Nikolettos; Alkiviadis Kostakis; Konstantinos Kontzoglou; Dimitrios Schizas; Afroditi Nonni
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Breast cancer under 40 years of age: increasing number and worse prognosis.

Authors:  Ágnes Dobi; Gyöngyi Kelemen; László Kaizer; Roland Weiczner; László Thurzó; Zsuzsanna Kahán
Journal:  Pathol Oncol Res       Date:  2010-09-17       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.